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High-density manually manufactured 3D hepatic models 
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Project goal 
The present project aims at evaluating the compatibility of a gelatin-
methacryloyl-based bioink with hepatocytes and its characterization. This 
study is the basis to generate bioprinted liver tissue-like models with co-
cultures of human hepatocytes, stellate and endothelial cells 
Key findings 
 Printing and characterization of HepG2 3D models as proof-of-concept 
 
 Establishment and evaluation of high-density hepatocytes models for 
bioprinting 
Figure 1 
A) Scheme used for layer-by-layer printing, drawn with BioCAD 
software (regenHU) 
B) MTT-staining of a bioprinted 4-layer HepG2-bionk model cultivated 
for 7 days (blue signal = viable cells) 
Conclusions 
 Bioprinting set up is established and demonstrates its suitability for the manufacture of well-defined and viable low cell density hepatic models.  
In the next step bioprinting will be used to simulate in vivo high cellular density conditions (hepatic high-density models) with additional relevant cell types, such 
as stellate and endothelial cells 
Project data 
 
Printing feasibility study 
 Bioprinting process as well as bioink is suitable for HepG2 
viability and proliferation 
 
 Printed HepG2 cells are homogenously distributed as single 
cells into the model forming agglomerates increasing in size 
over time 
A                             B 
Figure 2 
HepG2 cells / bioink mixture printed in 4-layers and cultivated for 1 (A) and 7 
days (B), respectively.  
Single cells: red arrows; cell agglomerates: blue arrows 
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Figure 3 
Viability and growth 
analysis of printed 3D 
models harbouring HepG2 
cells.  
 
Metabolically active cells  
were analysed by 
PrestoBlue assay.  
 
The relative fluorescence 
values of day1 samples 
were set as reference 
value at 1  
Figure 5 
HepG2-bioink drop models (7.5 *106 cells per model, 30ul model) cultivated up to 28 days and analysed for cell 
viability (ATP) and biological activity (albumin secretion) at day 1, 7, 14 and 28 
 High-density HepG2 models can be 
manually manufactured 
 
 HepG2 3D models show high and constant 
cell viability up to 14 days with a following 
decrease (d14 to d28)  
 
 Albumin production increases with time 
 
 Higher albumin amounts are obtained with 
vitamin C treated HepG2 models (d14 to 
d28) 
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Figure 4 
Manually manufactured models made of 
HepG2 high cell density paste mixed with 
bioink in a ratio of 2:1. 
18* 106 cells per disc model (70ul model): 
A) Disc model cultivated 1 day 
B) Disc model cultivated up to 28 days and 
stained with MTT 
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